Yale School of Medicine plans to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center with a gift from the Chênevert family.
The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
The National Comprehensive Cancer Network has published NCCN Guidelines for Histiocytosis.
A study led by Yale Cancer Center and Department of Neurology researchers demonstrated that a blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma.
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell therapy, to reduce the severity of treatment side effects.
City of Hope scientists have combined a checkpoint inhibitor with an anti-parasitic drug, ivermectin, to treat triple-negative breast cancer in preclinical research.
GO2 Foundation for Lung Cancer has created a multi-institutional study to determine how to improve the participation of Black communities in lung cancer clinical trials.
FDA has granted regular approval to Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test.
FDA has authorized marketing of the Hominis Surgical System, a new robotically-assisted surgical device that can help facilitate transvaginal hysterectomy in certain patients.
FDA has granted accelerated approval to Pepaxto (melphalan flufenamide) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.
